More Videos
SPECIAL REPORT
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Future of Marketing
- Priceline Crushes Profit Forecasts; Shares Jump
- Mad Mail: Buy the Berkshire Hathaway Split?
- European Commission Objects to Sun Micro-Oracle Deal
- Oil Tomorrow
- Framed for Porn – By a PC Virus
- Cramer: 5 Stocks to Play the Next Bull Run
- Sprint to Cut Up to 2,500 Jobs, Sees Charge
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
- European Commission Objects to Sun Micro-Oracle Deal
- Obama Sees Strains Unless US, China Balance Growth
- JPMorgan Lifts Salary Freeze Amid Recovery
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Do You Know Your Coca-Cola Myths?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
RSS FEED
Pharma's Market
Text Size 
 |
] put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million. DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes